Activated liver dendritic cells generate strong acquired immunity in α-galactosylceramide treatment

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1155-1162

  Sasakawa, Akira ^a,b   Tatsumi, Tomohide ^a,b   Takehara, Tetsuo ^a,b   Yamaguchi, Shinjiro ^a,b   Yamamoto, Masashi ^a,b   Ohkawa, Kazuyoshi ^a   Miyagi, Takuya ^a   Hayashi, Norio ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Galactosylceramide; Acquired antitumor immunity; Liver dendritic cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; LIVER CELL; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; IMMUNOTHERAPY; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; SPLEEN; SPLENIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349098197     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.027     Document Type: Article

References (25)

1. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. CD1d-restricted and TCR-mediated activation of Vα14NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
2. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-γ-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3 (2002) 867-874
3. Miyagi T., Takehara T., Tatsumi T., Kanto T., Suzuki T., Jinushi M., et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 106 (2003) 81-89
4. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., et al. Treatment of hepatic metastasis of the colon26 adenocacinoma with an α-galactosylceramide, KRN7000. Cancer Res 58 (1998) 1202-1207
5. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Vα24+Vβ11+NKT cells in human subjects results in highly coordinates secondary activation of acquired and innate immunity. Blood 103 (2004) 383-389
6. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8 (2002) 3702-3709
7. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
8. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
9. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 (2003) 267-279
10. Fujii S., Liu K., Smith C., Bonito A.J., and Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199 (2004) 1607-1618
11. Shortman K., and Liu T.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
12. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166 (2001) 6578-6584
13. Nakagawa R., Inui T., Nagafune I., Tazunoki Y., Motoki K., Yamauchi A., et al. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide. J Immunol 172 (2004) 6550-6557
14. Mayordomo J.I., Loftus D.J., Sakamoto H., De Cesare C.M., Appasamy P.M., Lotze M.T., et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183 (1996) 1357-1365
15. Tatsumi T., Takehara T., Yamaguchi S., Sasakawa A., Sakamori R., Ohkawa K., et al. Intrahepatic delivery of α-galatosylceramide pulsed dendritic cells suppresses liver tumor. Hepatology 45 (2007) 22-30
16. Yamaguchi S., Tatsumi T., Takehara T., Sakamori R., Uemura A., Mizushima T., et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 110 (2007) 1469-1477
17. Chaudhry U.I., Katz S.C., Kingham T.P., Pillarisetty V.G., Raab J.R., Shah A.B., et al. In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells. FASEB J 20 (2006) 982-984
18. Seino K., Motohashi S., Fujisawa T., Nakayama T., and Taniguchi M. Natural killer T cell-mediated anti-tumor immune responses and their clinical application. Cancer Sci 97 (2006) 807-812
19. Vremec D., and Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 159 (1997) 565-573
20. Nastala C.L., Edington H.D., McKinney T.G., Tahara H., Nalesnik M.A., Brunda M.J., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153 (1994) 1697-1706
21. Lasek W., Feleszko W., Golab J., Stoklosa T., Marczak T.M., Dabrowska A., et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45 (1997) 100-108
22. Pillarisetty V.G., Shah A.B., Miller G., Bleier J.I., and DeMatteo R.P. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 172 (2004) 1009-1017
23. Markus G., Traver D., Miyamoto T., Weissman I.L., and Akashi K. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97 (2001) 3333-3341
24. Belardelli F., and Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23 (2002) 201-208
25. Doherty D.G., and O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev 174 (2000) 5-20